Inserm Transfert, your partner for value creation and technology transfer

Inserm Transfert, founded in 2000, is the private subsidiary of Inserm, specialized in life sciences technology transfer and collaborative research projects funding. It works under a Public service Delegation Agreement (DSP).

0

patent families*

0

number of contracts and licenses*

* For the year 2021

0

millions of euros invested in Proof of concept

0

projects detected*

Serving research

The company supports Inserm research units and researchers in the process undertaken to create value from their work. Its actions are part of the translational continuum, from basic and technological research to clinical development, with the aim of creating economic and societal value.

Are you a Researcher?

Protecting my results
Involving companies
Funding my project
Thinking about entrepreneurship

Are you a Company?

A response dedicated to your needs
Our strategic areas of innovation
An exceptional offer
Plan France Relance en

Are you an Investor?

Investors

News

01 Jul 2022

Développer un projet entrepreneurial basé sur l'#innovation et la #santé : @InsermTransfert, chef de file du consor… https://t.co/jxMaGFNx2C

30 Jun 2022

RT @EHVA_EU: @CHUVLausanne @ChelwestFT @GHUMondor @EATGx @HorizonEU @IAVI @Inserm @SBFI_CH @MRCCTU EHVAT02 is taking place at sites in Fran…

28 Jun 2022

Antibody Industrial Symposium 2022, @InsermTransfert est présent aujourd'hui et demain à #Montpellier Venez rencon… https://t.co/jhuK7NkFmE

27 Jun 2022

@InsermTransfert félicite @ImcheckThx pour cette belle levée de fonds record de 96M€. Bravo pour cette belle… https://t.co/d835g8R8e9

24 Jun 2022

Le 10th Antibody Industrial Symposium #AIS2022, c'est la semaine prochaine, les 28-29 juin à Montpellier pour réuni… https://t.co/6wuGRtubHy

23 Jun 2022

Pré-lancement du projet https://t.co/8lX3Fs7LMg @InsermTransfert partenaire de ce projet #HorizonEurope, coordonné… https://t.co/PjvovWHjTJ

17 Jun 2022

@InsermTransfert partenaire du 10th Antibody Industrial Symposium #AIS2022 28-29 juin, Montpellier Organisé par… https://t.co/0V8udjhvwu

14 Jun 2022

@CongresCURIE Mireille Caralp, Directrice Données de santé & Recherche Clinique @InsermTransfert ce matin à l'ateli… https://t.co/ZGFb3jcwTh

14 Jun 2022

RT @CongresCURIE: La 2ème journée du #CongresCURIE va commencer. On espère que vous êtes en forme ! 💪 👉 Le programme est disponible ici :…

14 Jun 2022

#BIO2022 From June 13th to 16th, meet @InsermTransfert at BIO International Conference in San Diego, represented by… https://t.co/gRI4AzBCq6

14 Jun 2022

#BIO2022 @InsermTransfert est présent @CityofSanDiego pour participer à ce grand événement mondial des sciences de… https://t.co/WMQ2KzJiRX

13 Jun 2022

L'équipe d'@InsermTransfert vous attends au @CongresCURIE du 13 au 15 juin au Corum de Montpellier : Mélina Gaffré,… https://t.co/MUVTf1fbaY

10 Jun 2022

@CongresCURIE 13-15 juin Montpellier Mireille Caralp Directrice Données de santé & Recherche Clinique… https://t.co/dogExUrv42

09 Jun 2022

Inserm Transfert est partenaire du projet @hervcov projet de #médecine de précision lié aux #rétrovirus endogènes h… https://t.co/IDwsNmbh0d

07 Jun 2022

Répondez à l'Enquête Grand Public pour comprendre la perception des citoyens sur les perturbateurs endocriniens. P… https://t.co/Lp9USQSyZZ

02 Jun 2022

Vous êtes au #DeeptechTour de Paris, nous vous attendons ! https://t.co/pZhNSaLw9N

02 Jun 2022

#DeeptechTour Paris Table Ronde "j'ai un projet à qui je m'adresse ?" avec Pascale Augé, Stephanie Lefebvre et des… https://t.co/H5khh465Ou

02 Jun 2022

Venez nous retrouver au #DeeptechTour Paris aujourd'hui avec @paulinesoligna1 sur le stand d'@InsermTransfert et Pa… https://t.co/iLpazn7HI0

31 May 2022

Aujourd’hui Pascale Augé a présenté aux #startups et à l’écosystème de l’hôtel d’entreprise de @PariSanteCampus les… https://t.co/ZgV70qZfJ5

30 May 2022

#DeeptechTour Paris, 2 juin Pascale Augé participe à la Table Ronde "j'ai un projet à qui je m'adresse ?" avec le P… https://t.co/VeE7KQz0oZ

Collaborative projects

High-quality support for a research excellence.

RITA-MI 2

H2020

RITA-MI 2 will conduct a phase 2b randomised double-blind placebo-controlled CT to assess the impact of B cell depletion with the CD20 mAb rituximab on left ventricular dysfunction and cardiac ...

CBIG-SCREEN

H2020

CBIG-SCREEN aims to tackle inequality in cervical cancer screening (CCS) continuum. Though CCS programmes drastically reduce cervical cancer mortality, they remain largely inaccessible and ...

EHVA

H2020

 the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines.

...

EJP-RD

H2020

The European Joint Program on Rare Diseases brings over 130 institutions from 35 countries 27 EU Member States (Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, ...

REMEDIA

H2020

The overall objective of the REMEDIA project is to determine how and to what extent the exposome affects the severity and morbidity of Chronic Obstructive Pulmonary Disease (COPD) and Cystic ...

CARDIATEAM

IMI

Diabetic patients are 2.5 times more likely to develop heart failure than people without diabetes. In many patients, the diabetes causes a type of heart dysfunction called cardiomyopathy, which is ...

ENSAT-HT

H2020

This project will develop and evaluate an omics-based stratified health promotion program for patients with endocrine forms of hypertension.

...

COSY

RHU

The aim of our project is to transform the outcome and the medical care of patients with overgrowth syndromes (OS)

...

EU-TRAIN

H2020

"End stage renal diseases affect more than 3,900,000 patients worldwide with approximately 6% growth rate in 2016. Kidney transplantation is currently the best therapeutic option with around ...

KTD INNOV

RHU

"KTD-Innov combines molecular medicine (MM) and health information technology (HIT) to deliver a precision immune monitoring and diagnosis system applied in kidney transplantation: the Integrative ...

HUGODECA

H2020

"The HUGODECA project is a European funded research initiative investigating how human gonads (either an ovary or a testis) develop in the embryo in order to understand how the initially ...

CARMMA

RHU

CARMMA is based on the hypothesis that obesity co-morbidities are associated with an early senescence of adipose tissue (AT). The main objective of CARMMA is to determine the common and central ...

iVASC

RHU

iVASC est un consortium de chercheurs, de cliniciens et d’industriels, qui vise à mettre au point de nouveaux outils de recherche dans le domaine de l’athérothrombose et à les appliquer à ...

CARE

IMI

The CARE consortium is a coalition of 37 academic institutions, pharmaceutical companies and non-profit research organizations whose main objectives are the development of therapeutics (i) to ...

TheraLymph

H2020

Lymphedema is a disabling condition of localised accumulation of fluid in a tissue caused by a compromised lymphatic system. It is an incurable disease that affects millions of people worldwide and...

AB-DiRecT

IMI

Developing antibacterials for resistant infections. An alarming rise globally in antibiotic-resistant infections and a search for new solutions is the motivational force behind project AB-DiRecT. ...

IP-CURE-B

H2020

To develop novel curative concepts for chronic hepatitis B (CHB). The project aims to improve the cure rate of CHB by boosting innate immunity with immune modulators and stimulating adaptive immune...

VHFMoDRAD

IMI

VHFMoDRAD will develop and deliver rapid and point-of-care singel/multiplex diagnostic tool(s) that will significantly increase our capacity to handle outbreaks with Filoviruses and other viral ...

CCHFVaccine

H2020

The general aim of the CCHFVaccine project is to develop and deliver a vaccine, which can significantly increase our capacity to control the situation of Crimean Congo Haemorrhagic fever (CCHF) ...

ERINHA-Advance

H2020

One of the great challenges of the 21st century is to develop the capacity to prevent and react to outbreaks caused by highly pathogenic human and animal microorganisms, which are generally ...

EU-JAV

EU health programme

EU-JAV brings together the European Commission, health ministries, international policymakers and organisations, institutes, universities from 20 countries and a wide range of stakeholders, including ...

ZIKAlliance

H2020

ZIKAlliance is a multinational, multi-disciplinary research consortium comprised of 54 partners worldwide. It investigates clinical, fundamental, environmental and social aspects of ZIKV infection, in...

EBOVAC2

IMI

" The main objective of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBOV and MVA-BN-Filo vaccine....

R-LINK

H2020

The main objective of this study is to identify the eligibility criteria for treatment with lithium in bipolar I disorders (BDI) in terms of response, safety and tolerability. R-LiNK proposes a ...

QUID NASH

RHU

The main aim of the QUID-NASH program is to develop a virtual liver biopsy (non invasive) for the diagnosis and staging of NASH (Non Alcoholic SteatoHepatitis) in patients with type 2 diabetes,...

PREVAC-UP

The project PREVAC-UP is built around the PREVAC consortium. Its two primary objectives are to determine (i) the long-term immunogenicity and safety and (ii) durability of humoral and cellular ...

PREMSTEM

H2020

PREMSTEM aims to validate umbilical cord derived human mesenchymal stem cells as a regenerative therapy for encephalopathy of prematurity to improve the quality of life for preterm infants and ...

OBERON

H2020

The OBERON project will build an integrated approach for testing and assessment (IATA) to detect endocrine disruptors-related metabolic disorders by developing, improving and validating a battery of ...

MIROCALS

H2020

Efficacy and safety of low-dose IL2 (ld-IL2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients...

miniNO

H2020

The miniNO project will conduct out pioneering research on the connection between alterations in minipuberty and infantile nitric oxide (NO) signaling in the brain, and comorbidities that appear later...

MEDIT-AGEING

H2020

As the number of older people in Europe grows, increasing healthy life years is a priority. Cognitive decline, dementia (e.g. Alzheimer’s disease, AD), sleep disturbances and depression, all ...

MAD-CoV 2

IMI

The overall aim of MAD-CoV 2 project is to develop and deliver a treatment for COVID-19 patients, which will significantly increase our capacity to handle the current outbreak of SARS-CoV-2. In ...

JPsustaiND

H2020

The overall aim of JPsustaiND is to support the development and extension of the capacities of the EU Joint Programming Initiative on Neurodegenerative Diseases, in particular Alzheimer's (JPND). ...

JPcofuND2

H2020

With the objective of promoting research aimed at changing the trajectory of these debilitating diseases, JPco-fuND 2 launched in January 2019, a joint transnational call supported by 27 countries for...

JPco-fuND

H2020

This initiative launched a joint transnational call for proposals, as a joint effort of 20 countries, aimed at supporting international research collaborations in three JPND priority areas: ...

HERA

H2020

HERA will set the priorities for an environment and health research agenda in the EU by adopting a holistic and systemic approach in the face of global environmental changes. Research will support ...

HBM4EU

H2020

HBM4EU is a joint effort of 30 countries, the European Environment Agency and the European Commission, co-funded under Horizon 2020. The initiative is coordinating and advancing human biomonitoring in...

FAIR-PARK-II

H2020

"FAIR PARK II will primarily investigate the effects of an iron chelation therapy on the progression of handicap in Parkinson's disease.
The project will run for five years (2015 - 2020) and ...

FAIR

H2020

The project aims to assess an adjunct to antibiotic therapy as an emerging concept to overcome antimicrobial resistance in pneumonia. The research focuses on the unique immunomodulator flagellin that ...

EU-RESPONSE

H2020

The overall objective of this 5-year project is to build a multinational, adaptive European COVID-19 and emerging infectious diseases trial network, based on existing initiatives, experience and ...

EBRA

H2020

EBRA aims at reducing the fragmentation and duplication of research efforts and at fostering synergies through enhanced coordination of brain research efforts at the EU and global level....